Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VHH MHCII-antigen-dexamethasone conjugate
- Development stage
- Preclinical
- Lead developer
- Cerberus Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intranasal, Intravenous, Subcutaneous
01
Overview
VHH MHCII-antigen-dexamethasone conjugate (VHH MHCII-antigen-DEX) is a preclinical-stage trimodal nanobody-drug conjugate platform developed by Boston Children's Hospital and its spinout company, Cerberus Therapeutics, for the induction of antigen-specific immune tolerance in autoimmune diseases and allergies. The platform utilizes an alpaca-derived single-domain antibody fragment (nanobody/VHH) that targets major histocompatibility complex class II (MHCII) molecules on antigen-presenting cells (APCs). This nanobody is covalently conjugated to a disease- or allergen-specific peptide antigen (such as myelin oligodendrocyte glycoprotein for multiple sclerosis, citrullinated collagen for rheumatoid arthritis, insulin for type 1 diabetes, or ovalbumin/house dust mite for allergic asthma) and the anti-inflammatory corticosteroid dexamethasone (DEX). By delivering both the specific antigen and dexamethasone directly to APCs, the conjugate promotes the deletion, anergy, and regulatory differentiation of pathogenic antigen-specific T cells, thereby restoring long-lasting immune tolerance without causing systemic immunosuppression.
- Other names
- VHH MHCII-antigen-DEX conjugateVHHMHCII-antigen-DEX
02
Targets
γδ TCR (T-cell receptor)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on VHH MHCII-antigen-dexamethasone conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VHH MHCII-antigen-dexamethasone conjugate.